Latest news with #AmyTrombly
Business Insider
2 days ago
- Business
- Business Insider
Why Is Sonoma Pharmaceuticals Stock (SNOA) Up 105% Today?
Sonoma Pharmaceuticals (SNOA) stock underwent a massive rally on Thursday after its hypochlorous acid-based diaper cream for infants and children was launched at large retailers in the U.S. According to the company, this includes 3,600 Walmart (WMT) stores, Amazon (AMZN), and certain U.S. grocery chains. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Amy Trombly, CEO of Sonoma, said, 'We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels. We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations.' Sonoma Pharmaceuticals stock was up 103.8% in pre-market trading on Thursday, following a 1.73% rally yesterday. The shares were also up 13.46% year-to-date but have fallen 35.04% over the past 12 months. Today's news brought heavy trading to SNOA stock, with some 42 million shares traded, compared to a three-month daily average of about 84,000 units. Is Sonoma Pharmaceuticals Stock a Buy, Sell, or Hold? Turning to Wall Street, coverage of Sonoma Pharmaceuticals is lacking. Fortunately, TipRanks AI analyst Spark has it covered. Spark rates SNOA stock a Neutral (46) with a $3 price target. It cites 'poor financial performance characterized by declining revenues and negative cash flows' as reasons for this stance.
Yahoo
2 days ago
- Business
- Yahoo
Sonoma Pharmaceuticals Soars 95% After Walmart, Amazon Retail Debut
Aug 14 - Sonoma Pharmaceuticals (NASDAQ:SNOA) saw its stock skyrocket on Thursday morning, gaining nearly 95% after the company's first U.S. over-the-counter product hit major retail shelves. The hypochlorous acid-based diaper cream for infants and children is now available in 3,600 Walmart (NYSE:WMT) stores, on Amazon (NASDAQ:AMZN), and at select U.S. grocery chains. Warning! GuruFocus has detected 7 Warning Signs with SNOA. CEO Amy Trombly said this launch marks an important milestone in Sonoma's retail strategy. We are excited to see our strategy of expanding into the over-the-counter space begin to take hold, she noted, adding that the company aims to make its Microcyn technology widely accessible for parents looking for safe and effective solutions for diaper rash and other skin irritations. The market reaction was immediate. SNOA stock jumped as much as 95% building on a modest 1.7% gain the previous day. Year-to-date, shares are up 13.46%, though they remain down 35.04% over the past 12 months. Trading volume surged to 42 million shares, far exceeding the three-month daily average of about 84,000. With this retail rollout, Sonoma is betting that broader distribution and consumer visibility can help reverse its longer-term stock slump and accelerate its push into the consumer health space. This article first appeared on GuruFocus.
Yahoo
22-04-2025
- Business
- Yahoo
Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain
BOULDER, CO / / April 22, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its hypochlorous acid-based acne products with the Medicines & Healthcare products Regulatory Agency (MHRA) to be sold through a prominent U.K. health and beauty retailer and pharmacy chain across more than 1,200 stores throughout the United Kingdom. The innovative product line includes an acne toner and a balancing serum, both of which are available under the retailer's own brand name. "We are excited to bring our safe and effective acne line to consumers in the United Kingdom and to expand our range of distribution in Europe," said Amy Trombly, CEO of Sonoma. "These products utilize all-natural hypochlorous acid and our patented Microcyn technology formulation, providing a safe and gentle alternative to products containing harsh ingredients such as alcohol and benzoyl peroxide." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs or fund further development, as well as uncertainties relative to fluctuations in foreign currency exchange rates, global economic conditions, prospective tariffs or changes to trade policies, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: us on LinkedIn: us on Instagram: us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire
Yahoo
10-03-2025
- Business
- Yahoo
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
BOULDER, CO / / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant. "Thanks to the diligent efforts of our regulatory team in securing these new registrations with the MHRA, we are now able to bring our safe and effective Microcyn-based products to the United Kingdom," said Amy Trombly, CEO of Sonoma. "The U.K. represents a significant new market for Sonoma, for both our wound care and dermatology products, and we are excited for the opportunities for growth that this new registration provides." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Follow us on LinkedIn: Follow us on Instagram: Follow us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando
BOULDER, CO / / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, March 7-11, 2025. The AAD annual meeting is one of the leading dermatology conferences in the U.S., with over 350 exhibitors and close to 20,000 attendees, including more than 10,000 medical personnel, and more than 300 educational sessions. Founded in 1938 and headquartered in Rosemont, Illinois, AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails, advocating high standards in clinical practice, education, and research in dermatology, and supporting and enhancing patient care for a lifetime of healthier skin, hair, and nails. Its annual meeting provides an ideal opportunity to connect with peers and industry leaders while learning about the latest advancements in dermatology. Sonoma Pharmaceuticals is aiming to expand its distributor network and to showcase its line of prescription and OTC dermatology products. Interested parties are invited to visit Sonoma Pharmaceuticals' booth 1054to learn about its patented, innovative, safe, and effective products for skin care, scar management and atopic dermatitis. For more information, please visit "We are excited to attend AAD again this year and to present our portfolio of dermatology products at this highly regarded event," said Amy Trombly, CEO of Sonoma. "We look forward to bridging new connections for the continued distribution of our products and the increased availability of our safe and effective technology in the U.S." About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at For partnership opportunities, please contact busdev@ Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Website: us on LinkedIn: us on Instagram: us on Facebook: SOURCE: Sonoma Pharmaceuticals, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
